Compare AHMA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | GANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 159.2M |
| IPO Year | 2025 | 2021 |
| Metric | AHMA | GANX |
|---|---|---|
| Price | $39.50 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 12-08-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $19,771,050.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $667.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.00 | $1.41 |
| 52 Week High | $31.07 | $4.34 |
| Indicator | AHMA | GANX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.13 |
| Support Level | N/A | $1.75 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 21.75 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.